MarketVue®: Alopecia Areata
The MarketVue®: Alopecia Areata market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report: • Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:Research for the MarketVue®: Alopecia Areata report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.
Geographies covered:United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned: • Eli Lilly
• Incyte
• Pfizer
• Concert Pharmaceuticals
• AbbVie
• Suzhou Zelgen Biopharmaceuticals
• Legacy Healthcare
• Throne Biotechnologies
• Arena Pharmaceuticals
• Reistone Biopharma
• Bioniz Therapeutics / Equillium
Key drugs mentioned: • Injectable and topical steroids
• Minoxidil (Rogaine)
• Methotrexate (Trexall, Rheumatrex)
• Diphencyprone (DPCP)
• Tacrolimus (Prograf , Protopic)
• Baricitinib (Olumiant)
• Tofacitinib (Xeljanz)
• Dupilumab (Dupixent)
• Ruxolitinib (Jakafi, Opzelura)
• Adalimumab (Humira)
• Upadacitinib (Rinvoq
• Ritlecitinib (Litfulo)
• Coacillium
• Stem Cell Educator (SCE) therapy
• Etrasimod (Velsipity)
• SHR0302
• BNZ-1
• Jaktinib
Please note: the online download version of this report is for a global site license.